PTA

OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China

Retrieved on: 
수요일, 4월 24, 2024
Tricuspid valve, FDA, TMVR, Hope, Hospital, Percutaneous coronary intervention, NMPA, Safety, Valvular heart disease, OrbusNeich, PCI, TAVR, Patient, PTA, Zhongshan Hospital, Fudan University, Cardiology, Aortic stenosis, Clinical trial, Quality of life, Medical device

The CE-marked medical device was named a Breakthrough Device and an Innovative Medical Device by the FDA in the United States and NMPA in China, respectively.

Key Points: 
  • The CE-marked medical device was named a Breakthrough Device and an Innovative Medical Device by the FDA in the United States and NMPA in China, respectively.
  • It has effectively treated a 56-year-old patient with severe tricuspid regurgitation, marking the commencement of the clinical trial across Mainland China.
  • Led by principal investigator Prof. Ge Junbo, Academician Zhongshan Hospital, Fudan University, and his team, the clinical trial aims to assess the safety and efficacy of TricValve.
  • Mr. Peter Peh, General Manager of OrbusNeich P&F, said, "We are pleased to see TricValve moving into clinical trial, marking the first successful implantation of a percutaneous transcatheter bicaval device in a patient by cardiologists in Mainland China, to address severe tricuspid valve regurgitation.

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Retrieved on: 
수요일, 5월 8, 2024
Hearing, Safety, Food, ABR, Regeneron Pharmaceuticals, Cell, Research, Gold, Sound, PTA, Society, Gene, Otorhinolaryngology, Child, Ear, Orphan drug, European Medicines Agency

TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) within 24 weeks, and initial hearing improvements were observed in a second child (dosed at 4 years of age) at a 6-week assessment. Both children were born with profound genetic deafness due to variants of the otoferlin gene, and the child dosed at 11 months of age is one of the youngest in the world to receive a gene therapy for genetic deafness. The results are from the ongoing Phase 1/2 CHORD trial, which is currently enrolling infants and children and were detailed during an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) annual conference.

Key Points: 
  • The surgical procedure leverages the same approach used for cochlear implants, which is amenable for use in young infants.
  • Hearing improvements were assessed by pure tone audiometry (PTA) and auditory brainstem response (ABR).
  • At baseline, both participants had no behavioral (PTA) or electrophysiological (ABR) responses at maximum sound levels (≥100 dB).
  • The potential use of DB-OTO for otoferlin-related hearing loss is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

AdvoCare® Honors Richardson ISD Teachers and Staff During Teacher Appreciation Week

Retrieved on: 
수요일, 5월 8, 2024
Preschool, Food, Beverage, Women, Retail, Parenting, Men, Children, Family, Electronic Commerce, Consumer, Fitness & Nutrition, Technology, General Health, Health, Other Education, Specialty, Primary, Secondary, Education, CMO, GO, George, School, Lake Highlands High School, Sambucus, RISD, PTA, AdvoCare, Harmony, Multimedia, Richardson Independent School District, Tutoring

AdvoCare International, LLC , a health and wellness e-commerce company, actively sought opportunities to support the dedicated educators within its community showing appreciation to them across three campuses within Richardson ISD (RISD) during Teacher Appreciation Week, May 6-10.

Key Points: 
  • AdvoCare International, LLC , a health and wellness e-commerce company, actively sought opportunities to support the dedicated educators within its community showing appreciation to them across three campuses within Richardson ISD (RISD) during Teacher Appreciation Week, May 6-10.
  • AdvoCare donated a total of $3,000 to three schools within RISD – Forest Meadow Junior High, Spring Creek Elementary, and Lake Highlands High School.
  • "By supporting Richardson ISD teachers and staff, we aim to express our heartfelt gratitude for their unwavering dedication to shaping our future generations.
  • AdvoCare will also accept nominations via their @AdvoCare Instagram to fulfill teachers’ Amazon Wish Lists, granting up to $500 per winner.

A Role Model in Her Community: Regions Bank Branch Manager Honored for Making an Impact on Others

Retrieved on: 
수요일, 4월 24, 2024
Professional Services, Philanthropy, Other Consumer, Consumer, Other Philanthropy, Finance, Banking, Education, Service award, Cancer, National Volunteer Week, Hope, Teaching, Heart, Happiness, Lunch, Human, Life, Regions Financial Corporation, PTA, Bank, Birmingham Civil Rights Institute, Commerce, Multimedia, Student, The Front Porch, MIT

Regions Bank on Wednesday announced Kascia Polk, manager of Regions’ Villa Rica, Georgia, branch, has been awarded the 2024 Lee Ann Petty Heart of Service Award, Regions’ highest honor for community involvement.

Key Points: 
  • Regions Bank on Wednesday announced Kascia Polk, manager of Regions’ Villa Rica, Georgia, branch, has been awarded the 2024 Lee Ann Petty Heart of Service Award, Regions’ highest honor for community involvement.
  • Longtime Regions associate Lee Ann Petty served as volunteer services coordinator in Regions’ Community Affairs division.
  • Regions is proud to honor Kascia Polk with the award that pays tribute to Petty’s legacy.
  • “I’m honored and humbled to be recognized with the Lee Ann Petty Heart of Service Award,” Polk said.

Southeast Seattle Schools Collaborative Fundraiser seeks community support to raise funds

Retrieved on: 
일요일, 4월 21, 2024
SPS, Learning, School, Parent, Student, Seattle Public Schools, Friends, Washington State, Lotus, PTA, PTAS, Patent, Social justice, K-8, Tutoring

SEATTLE, April 21, 2024 /PRNewswire-PRWeb/ -- The fourth annual move-a-thon fundraiser, led by Southeast Seattle Schools Fundraising Alliance, will kick off on Monday, April 22, and run (literally!)

Key Points: 
  • SEATTLE, April 21, 2024 /PRNewswire-PRWeb/ -- The fourth annual move-a-thon fundraiser, led by Southeast Seattle Schools Fundraising Alliance, will kick off on Monday, April 22, and run (literally!)
  • ) through Friday, May 3, to benefit approximately 7000 students attending 17 elementary, K-8 and middle schools in District 7 of Seattle Public Schools.
  • The collaborative fundraising effort aims to raise $500,000 for schools who have historically been unable to raise the kind of funds typically generated by parent organizations elsewhere in the district.
  • This year, the Southeast Seattle Schools Fundraising Alliance will again engage students in participating in a bingo board-based move-a-thon to raise money.

GCC Polyethylene Terephthalate Market Analysis Report 2024: PET's Role in Eco-Friendly Packaging Solutions and Versatility in Automotive Applications - Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
화요일, 3월 26, 2024
Packaging, Recycling, Chemicals, Plastics, Automotive Manufacturing, Environment, Manufacturing, MEG, PTA, Urbanization, Growth, Sport, Application, Dow Chemical Company, International, COVID-19, SABIC, PET, Transport, Food, Private sector, RPET, Ethylene glycol, Supply, GCC, Vision 2030, Tourism, Drink, Water, Compound annual growth rate, Polyethylene terephthalate, JBF, Food safety, Food industry, Bottled water

GCC PET market demand is forecasted to grow at a CAGR of 5.30% over the projected period of 2024-2029.

Key Points: 
  • GCC PET market demand is forecasted to grow at a CAGR of 5.30% over the projected period of 2024-2029.
  • GCC PET supply is expected to reach 3.61 million ton by 2029, while GCC PET demand in 2023 stood at 2.20 million ton.
  • Polyethylene Terephthalate (PET), formed by combining purified terephthalic acid (PTA) or dimethyl terephthalate with modified ethylene glycol, exhibits notable impact resistance and ensures food safety.
  • The GCC Polyethylene Terephthalate (PET) market is characterized by a moderately concentrated landscape with several established players vying for market share.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
목요일, 3월 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics

Retrieved on: 
수요일, 3월 13, 2024
Health Technology, Other Health, Technology, Oncology, General Health, Medical Devices, Neurology, Other Technology, Cardiology, Science, Biotechnology, Software, Other Science, Health, Research, PTA, Genome, Gene expression, Transcriptome, DNA, RNA, Figure skating jumps, Marketing, Workflow, Data, Genomics, SVS, WGA, Antibiotics

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.
  • As part of these new kit configurations, total workflow time has been reduced to under eight hours for both products.
  • “These new core kits provide researchers with an optimized and validated workflow that delivers industry-leading single-cell multiomic performance,” said Suresh Pisharody, CEO, BioSkryb.
  • The ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit leverages its PTA-based WGA technology to couple each single cell’s whole genome with its full-length whole transcriptome.

SABER College Opens Enrollment for Comprehensive Physical Therapist Assistant A.S. Degree Program

Retrieved on: 
수요일, 3월 27, 2024
SABER, PTA, Employment, Therapy, Health, Associate, Anatomy, Education, Patient, School, Pell Grant, Interview, Admission, Faculty, Student, Marketing, Mathematics, Curriculum, Workforce, Language, Physical, Nursing

MIAMI, March 27, 2024 /PRNewswire/ -- SABER College is pleased to announce the enrollment opening for its Physical Therapist Assistant (PTA) Associate of Science (A.S.) degree program .

Key Points: 
  • MIAMI, March 27, 2024 /PRNewswire/ -- SABER College is pleased to announce the enrollment opening for its Physical Therapist Assistant (PTA) Associate of Science (A.S.) degree program .
  • Delivered entirely in English, the Physical Therapist Assistant A.S. degree program at SABER College prepares students to enter the dynamic field of healthcare confidently.
  • "Our Physical Therapist Assistant program is a testament to SABER College's unwavering dedication to nurturing individuals' educational aspirations and fostering their evolution into conscientious contributors to society.
  • To be accepted into the Physical Therapist Assistant Program , applicants must meet the following requirements:
    Submission of a SABER college application, including a writing sample
    Attainment of a minimum score of 11.0 in mathematics, language, and reading on the TABE Test (Students with an A.A. degree or higher are exempt)
    For more information about the Physical Therapist Assistant A.S. degree program at SABER College and to begin your journey toward a rewarding healthcare career, visit www.sabercollege.edu or call (305) 443-9170.

OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share

Retrieved on: 
목요일, 3월 7, 2024
Stent, Acquisition, MDR, Education, Cardiac catheterization, Sapphire, FDA, Marketing, Quality of life, Medical device regulation, PTCA, Physician, Growth, OrbusNeich, Medicare, PMDA, PTA, Abbott Laboratories, Percutaneous coronary intervention, Patient, Clinical trial, Knowledge, NMPA, Laboratory, Research, PCI

-- Revenue hit record high at US$153.9 million, up 12.5% year-on-year

Key Points: 
  • -- Revenue hit record high at US$153.9 million, up 12.5% year-on-year
    -- Revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year, respectively.
  • In particular, revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year to US$115.4 million and US$14.7 million, respectively.
  • As at December 31, 2023, the Group was in a strong financial position with cash and bank balances amounting to US$255.8 million (2022: US$229.1 million).
  • Having considered future capital requirements, the Board has proposed a final dividend of HK10 cents per share in cash, as a token of appreciation for the continuous support of shareholders.